https://www.live-feeds.com/feed/experimental-lilly-combination-drug-tops-zepbound-in-weight-loss-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/experimental-lilly-combination-drug-tops-zepbound-in-weight-loss-trialhttps://www.live-feeds.com/feed/experimental-lilly-combination-drug-tops-zepbound-in-weight-loss-trial#u100202Sun, 04 Oct 2026 21:32:11 +0000Eli Lilly reported that its experimental combination drug EloraTZP outperformed Zepbound in a head-to-head mid-stage trial. Patients with diabetes receiving the highest tested dose of EloraTZP lost an average of 23.3% of their body weight, compared to 14.8% for those receiving tirzepatide alone. EloraTZP combines tirzepatide with the experimental amylin drug eloralintide. Following these results, the Indianapolis-based pharmaceutical company plans to initiate Phase 3 trials for the combination regimen by the end of 2026.Why it mattersLilly is competing with Novo Nordisk to develop more effecti